ESC Professional Premium Access

Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials in type 2 diabetes: a meta-analysis of individual patient data

Congress Session

About the speaker

Mr Georg Wolff

University Hospital Duesseldorf, Duesseldorf (Germany)
0 follower

5 more presentations in this session

The DPP4 inhibitor linagliptin exacerbated heart failure due to energy deficiency via downregulation of glucose absorption and utilization in mice.

Speaker: Doctor A. Shiraki (Saga, JP)

Thumbnail

Empagliflozin rescues primary murine cardiac fibroblasts, but not cardiomyocytes, from hypoxia-reoxygenation injury through STAT3-mediated cascades.

Speaker: Mrs P. Nikolaou (Athens, GR)

Thumbnail

Anti-inflammatory potential of SGLT2 inhibitors: a systematic review and meta-analysis of preclinical studies in rodents

Speaker: Doctor M. Sagris (Athens, GR)

Thumbnail

Four-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus.

Speaker: Doctor I. Ikonomidis (Athens, GR)

Thumbnail

Adherence and discontinuation of sglt2-inhibitors and glp1-r agonists in patients with type 2 diabetes with and without cardiovascular disease

Speaker: Doctor M. Malik (Copenhagen, DK) Doctor A. Falkentoft (Roskilde, DK)

Thumbnail

Access the full session

Anti-diabetic pharmacotherapy in clinical practice

Speakers: Mr G. Wolff, Doctor A. Shiraki, Mrs P. Nikolaou, Doctor M. Sagris, Doctor I. Ikonomidis...
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

This platform is supported by

logo Novo Nordisk